BioCentury | Nov 14, 2011
Regulation

Inching toward feasibility

...completed Warner Chilcott plc (NASDAQ:WCRX)/TaiGen Biotechnology Co. Ltd. Nemonoxacin Topoisomerase IV inhibitor Ph II completed Dong Wha Pharmaceutical Industrial Co. Ltd....
BioCentury | Jan 31, 2011
Finance

IPO price watch

...are expected mid-2012. Iaso (formerly Pacific Beach BioSciences Inc.) has exclusive rights to zabofloxacin from Dong Wha Pharmaceutical Industrial Co. Ltd....
...trial. But Iaso will require additional funds beyond an IPO to conduct Phase III testing. Dong Wha...
BioCentury | Jan 25, 2011
Financial News

Clarus, Iaso Pharma set IPO ranges

...community-acquired pneumonia (CAP). Iaso (formerly Pacific Beach BioSciences Inc.) has exclusive rights to zabofloxacin from Dong Wha Pharmaceutical Industrial Co. Ltd....
BioCentury | Dec 28, 2010
Financial News

Iaso Pharma changes underwriter

...community-acquired pneumonia (CAP). Iaso (formerly Pacific Beach BioSciences Inc.) has exclusive rights to zabofloxacin from Dong Wha Pharmaceutical Industrial Co. Ltd....
BioCentury | Apr 19, 2010
Finance

IPO watch

...community-acquired pneumonia (CAP). IASO has exclusive rights to zabofloxacin to treat bacterial respiratory infections from Dong Wha Pharmaceutical Industrial Co. Ltd....
BioCentury | Apr 17, 2010
Financial News

Iaso Pharma files for IPO

...community-acquired pneumonia (CAP). Iaso (formerly Pacific Beach BioSciences Inc.) has exclusive rights to zabofloxacin from Dong Wha Pharmaceutical Industrial Co. Ltd....
BioCentury | Aug 20, 2007
Company News

Pacific Beach BioSciences Inc, Dong Wha deal

...Pacific Beach received exclusive rights to develop and commercialize Dong Wha's zabofloxacin ( PB-101 ) outside of...
...outside of Australia, New Zealand and certain Asian territories to treat bacterial respiratory infections. Dong Wha...
...fluoroquinolone antibiotic has completed Phase I testing. Pacific Beach BioSciences Inc ., San Diego, Calif. Dong Wha Pharmaceutical Industrial Co. Ltd....
BioCentury | Jul 16, 2007
Strategy

Gambling on partnerships

...Procter & Gamble Pharmaceuticals Inc.'s deal with Dong Wha Pharmaceutical Industrial Co. exemplifies how the consumer product...
...and their doctors about the product when it reached market. Under this month's deal with Dong Wha...
...PG received exclusive, worldwide rights outside certain Asian countries including Japan, Korea and China, to Dong Wha's...
BioCentury | Jul 16, 2007
Strategy

All outsourced

...All outsourced Year Partner Deal Current status [status at time of deal] 2007 Dong Wha Develop and...
BioCentury | Jul 9, 2007
Company News

Dong Wha, P&G deal

...The deal includes Dong Wha's lead osteoporosis compound, DW1350 , which is in Phase I testing. Dong Wha...
...total of $511 in an undisclosed upfront payment and milestones and is eligible for royalties. Dong Wha Pharmaceutical Industrial Co. Ltd....
Items per page:
1 - 10 of 12
BioCentury | Nov 14, 2011
Regulation

Inching toward feasibility

...completed Warner Chilcott plc (NASDAQ:WCRX)/TaiGen Biotechnology Co. Ltd. Nemonoxacin Topoisomerase IV inhibitor Ph II completed Dong Wha Pharmaceutical Industrial Co. Ltd....
BioCentury | Jan 31, 2011
Finance

IPO price watch

...are expected mid-2012. Iaso (formerly Pacific Beach BioSciences Inc.) has exclusive rights to zabofloxacin from Dong Wha Pharmaceutical Industrial Co. Ltd....
...trial. But Iaso will require additional funds beyond an IPO to conduct Phase III testing. Dong Wha...
BioCentury | Jan 25, 2011
Financial News

Clarus, Iaso Pharma set IPO ranges

...community-acquired pneumonia (CAP). Iaso (formerly Pacific Beach BioSciences Inc.) has exclusive rights to zabofloxacin from Dong Wha Pharmaceutical Industrial Co. Ltd....
BioCentury | Dec 28, 2010
Financial News

Iaso Pharma changes underwriter

...community-acquired pneumonia (CAP). Iaso (formerly Pacific Beach BioSciences Inc.) has exclusive rights to zabofloxacin from Dong Wha Pharmaceutical Industrial Co. Ltd....
BioCentury | Apr 19, 2010
Finance

IPO watch

...community-acquired pneumonia (CAP). IASO has exclusive rights to zabofloxacin to treat bacterial respiratory infections from Dong Wha Pharmaceutical Industrial Co. Ltd....
BioCentury | Apr 17, 2010
Financial News

Iaso Pharma files for IPO

...community-acquired pneumonia (CAP). Iaso (formerly Pacific Beach BioSciences Inc.) has exclusive rights to zabofloxacin from Dong Wha Pharmaceutical Industrial Co. Ltd....
BioCentury | Aug 20, 2007
Company News

Pacific Beach BioSciences Inc, Dong Wha deal

...Pacific Beach received exclusive rights to develop and commercialize Dong Wha's zabofloxacin ( PB-101 ) outside of...
...outside of Australia, New Zealand and certain Asian territories to treat bacterial respiratory infections. Dong Wha...
...fluoroquinolone antibiotic has completed Phase I testing. Pacific Beach BioSciences Inc ., San Diego, Calif. Dong Wha Pharmaceutical Industrial Co. Ltd....
BioCentury | Jul 16, 2007
Strategy

Gambling on partnerships

...Procter & Gamble Pharmaceuticals Inc.'s deal with Dong Wha Pharmaceutical Industrial Co. exemplifies how the consumer product...
...and their doctors about the product when it reached market. Under this month's deal with Dong Wha...
...PG received exclusive, worldwide rights outside certain Asian countries including Japan, Korea and China, to Dong Wha's...
BioCentury | Jul 16, 2007
Strategy

All outsourced

...All outsourced Year Partner Deal Current status [status at time of deal] 2007 Dong Wha Develop and...
BioCentury | Jul 9, 2007
Company News

Dong Wha, P&G deal

...The deal includes Dong Wha's lead osteoporosis compound, DW1350 , which is in Phase I testing. Dong Wha...
...total of $511 in an undisclosed upfront payment and milestones and is eligible for royalties. Dong Wha Pharmaceutical Industrial Co. Ltd....
Items per page:
1 - 10 of 12